PER® Miami Breast Cancer Conference

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

In this podcast, Maisam Fazel, FRCS, MS, MB BChir, discusses his research into a checklist for breast cancer surgeons.

Dr. Daniel Osman, director of the Miami Breast Cancer Conference, on Designing the Program for the MBCC

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

As the number of breast cancer survivors grows, so does the emphasis on establishing individualized survivorship plans

Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response

Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response

With thousands of clinical trials in play, many oncology specialists are reluctant to embrace findings from newly-released studies

Personalized treatment in oncology is a popular concept these days, but the goal remains elusive

It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ

The addition of sorafenib to capecitabine as a first-line therapy for patients with advanced breast cancer

Daniel A. Osman, MD, Founder and Course Director of the Miami Breast Cancer Conference Discusses Methods for Detecting Malignant Conditions in Breast Cancer

The climate for medical malpractice litigation in breast cancer treatment seems to be worsening

Breast pain is among the most common reasons that women seek medical attention from a breast specialist.